A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
Stopped early · Phase 2
Conditions studied: ADHD
In brief
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
Key facts
- Study ID
- NCT06673368
- Run by
- Neurocentria, Inc.
- People needed
- 2
- Starts
- 2025-02-25
- Expected to finish
- 2025-07-15
- Last updated by the study team
- 2026-01-15
Who can join
Age: 13 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Accel Research Site-Maitland Clinical Research Unit — Maitland, Florida, United States
- iResearch Atlanta — Decatur, Georgia, United States
- CenExel iRS - iResearch Savannah — Savannah, Georgia, United States
- Boston Clinical Trials LLC — Boston, Massachusetts, United States
- Center For Psychiatry and Behavioral Medicine — Las Vegas, Nevada, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.